ANPCY News and Press, Angle Plc Surrey ADR From 11/11/21

Study in metastatic prostate cancer presented at NCRI Festival demonstrates longitudinal analysis of CTCs harvested using the Parsortix system is predictive of treatment response KLK2 gene expression on CTCs found to be a more effective biomarker for assessing likelihood of cancer progr...

GUILDFORD, SURREY / ACCESSWIRE / November 2, 2021 / ANGLE plc ("the Company") Change of advisers ANGLE plc (OTCQX:ANPCY)(AIM:AGL), a world-leading liquid biopsy company, is pleased to announce the appointments of Berenberg as its Nominated Adviser and Joint Broker and Jefferies as its Joint...

PARSORTIX SYSTEM DEMONSTRATES ABILITY TO ISOLATE CTCs FOR DOWNSTREAM GENE ANALYSIS REVEALING MULTIPLE PROGNOSTIC BIOMARKERS Leading European study centre presents results of three studies in ovarian and lung cancer at 5 th ACTC Conference Novel CTC biomarkers found to predict prog...

Study demonstrates use of Parsortix to assess PD-L1 Status of CTCs in Non-Small Cell Lung Cancer patients with a simple blood test Further evidence supporting ANGLE's decision to develop a Parsortix-based PD-L1 assay to assess patient cancer PD-L1 status ANGLE PD-L1 assay to be off...

PARSORTIX SYSTEM ENABLES GENE EXPRESSION ANALYSIS IN METASTATIC PROSTATE CANCER PATIENTS Parsortix able to isolate CTCs in 80% of patients providing access to tumour material for gene expression analysis when tissue biopsy not feasible Longitudinal patient monitoring using Parsorti...

GUILDFORD, SURREY / ACCESSWIRE / September 7, 2021 / ANGLE plc (AIM:AGL)(OTCQX:ANPCY), a world-leading liquid biopsy company, will be releasing its interim results for the six months ended 30 June 2021 on Thursday 30 September 2021. A virtual meeting and webcast for analysts will be held at...

PUBLICATION HIGHLIGHTS EASE OF USE AND SUPERIOR PERFORMANCE OF PARSORTIX SYSTEM IN HARVESTING CTCs FROM METASTATIC BREAST CANCER PATIENTS Quantity, purity and quality of CTCs captured using the Parsortix system shown to be superior to an alternative antibody-based approach Study su...

ANGLE to develop two custom CTC assays to look at biomarkers of DNA damage repair Validated assays expected to be used for longitudinal analysis in clinical trial GUILDFORD, SURREY / ACCESSWIRE / July 28, 2021 / ANGLE plc (AIM:AG)(OTCQX:ANPCY), a world-leading liquid biopsy c...

PARSORTIX USED TO SUCCESSFULLY HARVEST CANCER CELLS FOR ANALYSIS FROM THE BLOOD OF PATIENTS WITH BRAIN METASTASIS Parsortix successful in overcoming challenges associated with isolating CTCs from brain metastasis patients in three different cancer types Analysis of CTCs may enable ...

ANGLE plc Director/PDMR Shareholding Exercise of Options and Total Voting Rights GUILDFORD, SURREY / ACCESSWIRE / July 7, 2021 / ANGLE plc ('ANGLE' or the 'Company') (AIM:AGL) (OTCQX:ANPCY), a world-leading liquid biopsy company, announces that it has agreed to allot 1,023,826 new ordin...